Uncategorized

Can-Fite Announces Final Data Analysis from Phase II NASH Study: Highly Significant and Sustained Reduction in Liver Fat Volume

PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that the final data analysis from its Phase II study of Namodenoson in the treatment of patients with non-alcoholic fatty …

Read More »

Pairnomix Launches Screening Services Assisting Physicians to Identify Treatments Based on Rare Genetic Mutations

MAPLE GROVE, Minn., Sept. 28, 2016 /PRNewswire/ — Pairnomix, LLC, a genetic research company and member of the Patient-Empowered Precision Medicine Alliance (PEPMA) recognized by the White House, today reported on the successful launch of its unique characterization and drug screening services that provide physicians with data on a patient’s …

Read More »

Unexplained Developmental Disorder Linked to Gene Involved in Essential Cellular Process

HOUSTON – (Aug.18, 2016) – A neurodevelopmental disorder for which there was no known cause has been linked to SON, a gene that is involved in essential mechanisms a cell uses to translate DNA into protein, as well as in DNA replication and cell division. A multidisciplinary, international team of …

Read More »

CVS Health Reports Drop in Prescription Drug Trend to 5 Percent

WOONSOCKET, R.I., Feb. 23, 2016 /PRNewswire/ –CVS Health (NYSE: CVS) today announced that prescription drug trend, a measure of growth in prescription spending, for CVS Health pharmacy benefit management (PBM) clients dropped dramatically to 5 percent in 2015 from a high of 11.8 percent in 2014. While the trend drivers …

Read More »

FDA Panel Backs Pfizer and Celltrion’s Proposed Biosimilar Infliximab

Pfizer Inc. commends today’s recommendation by the United States (U.S.) Food and Drug Administration’s (FDA) Arthritis Advisory Committee to approve the investigational biosimilar infliximab (CT-P13) across all eligible indications by a vote of 21 to three. Celltrion’s proposed biosimilar infliximab, to which Pfizer holds exclusive U.S. commercialization rights, is the …

Read More »

Timely Treatment

When one analyzes the medical records of 1.6 American adults, it turns out there’s a lot to be learned there. Researchers with the Chronic Hepatitis Cohort Study (CHeCS) did just that starting back in 2006 and tracked the ongoing health of those with hepatitis for the next numerous years. As …

Read More »

Celgene Enters $105 Million Cancer Immunotherapy Collaboration with Lycera

Celgene has entered into a new cancer immunotherapy deal that could provide privately-held Lycera Corp. up to $105 million-plus. Lycera announced the formation of an exclusive global collaboration with Celgene to advance Lycera’s proprietary pipeline for cancer and immune-mediated diseases. Lycera said that Celgene will license its portfolio of RORgamma …

Read More »